SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Anis KV, Rajeshkumar NV, Kuttan R. 2001. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 53: 763768.
  • Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 15791585.
  • Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A, Kaltschmidt C, Neumann FJ, Mackman N, Baeurele PA, Walli AK, Neumeier D. 1997. Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 17: 19011909.
  • Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. 1996. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97: 17151722.
  • Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. 1997. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 82: 297304.
  • Chase AJ, Bond M, Crook MF, Newby AC. 2002. Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 22: 765771.
  • Chen FL, Yang ZH, Liu Y, Li LX, Liang WC, Wang XC, Zhou WB, Yang YH, Hu RM. 2008. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine 33: 331337.
  • Choi SH, Cho SK, Kang SS, Bae CS, Bai YH, Lee SH, Pak SC. 2003. Effect of apitherapy in piglets with preweaning diarrhea. Am J Chin Med 31: 321326.
  • Doggrell SA. 2005. Berberine—a novel approach to cholesterol lowering. Expert Opin Investig Drugs 14: 683685.
  • Fiotti N, Altamura N, Orlando C, Simi L, Reimers B, Pascotto P, Zingone B, Pascotto A, Serio M, Guarnieri G, Giansante C. 2008. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol 127: 350357.
  • Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. 1995. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 92: 402406.
  • Guo Y, Wang QZ, Li FM, Jiang X, Zuo YF, Wang L. 2008. Biochemical pathways in the antiatherosclerotic effect of berberine. Chin Med J (Engl) 121: 11971203.
  • Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. 2005. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 11971205.
  • Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI. 2000. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci U S A 97: 90529057.
  • Haug C, Lenz C, Diaz F, Bachem MG. 2004. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase Inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 18231829.
  • Hsieh YS, Kuo WH, Lin TW, Chang HR, Lin TH, Chen PN, Chu SC. 2007. Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells. J Agric Food Chem 55: 1043710445.
  • Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L, Wang Y, Chen T. 2008. Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 374: 517521.
  • Huang Z, Wang L, Meng S, Wang Y, Chen T, Wang C. 2009. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int J Cardiol 146: 153158.
  • Ikram M. 1975. A review on the chemical and pharmacological aspects of genus Berberis. Planta Med 28: 353358.
  • Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. 1998. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32: 368372.
  • Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 13441351.
  • Kunte H, Amberger N, Busch MA, Ruckert RI, Meiners S, Harms L. 2008. Markers of instability in high-risk carotid plaques are reduced by statins. J Vasc Surg 47: 513522.
  • Lee TS, Pan CC, Peng CC, Kou YR, Chen CY, Ching LC, Tsai TH, Chen SF, Lyu PC, Shyue SK. 2010. Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages. J Cell Biochem 111: 104110.
  • Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB. 2006. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 22562264.
  • Libby P. 2001. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104: 365372.
  • Lu Y, Wahl LM. 2005. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol 78: 259265.
  • Lusis AJ. 2000. Atherosclerosis. Nature 407: 233241.
  • Majdalawieh A, Ro HS. 2010. Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm, Submitted for publication.
  • Major TC, Liang L, Lu X, Rosebury W, Bocan TM. 2002. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 22: 200207.
  • Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. 2000. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 43: 801811.
  • Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. 2004. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A 101: 56345639.
  • Ogawa K, Chen F, Kuang C, Chen Y. 2004. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J 381: 413422.
  • Rajavashisth TB, Yamada H, Mishra NK. 1995. Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-kappa B. Arterioscler Thromb Vasc Biol 15: 15911598.
  • Schmidt R, Bultmann A, Fischel S, Gillitzer A, Cullen P, Walch A, Jost P, Ungerer M, Tolley ND, Lindemann S, Gawaz M, Schomig A, May AE. 2008. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 102: 302309.
  • Schmidt R, Bultmann A, Ungerer M, Joghetaei N, Bulbul O, Thieme S, Chavakis T, Toole BP, Gawaz M, Schomig A, May AE. 2006. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 113: 834841.
  • Shin J, Edelberg JE, Hong MK. 2003. Vulnerable atherosclerotic plaque: clinical implications. Curr Vasc Pharmacol 1: 183204.
  • Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. 2000. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci U S A 97: 14331437.
  • Thiemermann C. 2004. Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size. Cardiovasc Res 63: 810.
  • Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, Tada K. 1982. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 42: 15301506.
  • Wilson SH, Best PJ, Edwards WD, Holmes DR, Jr., Carlson PJ, Celermajer DS, Lerman A. 2002. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 160: 147153.
  • Wolfrum S, Teupser D, Tan M, Chen KY, Breslow JL. 2007. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes. Proc Natl Acad Sci U S A 104: 1860118606.
  • Yamamoto Y, Gaynor RB. 2004. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 29: 7279.
  • Yin J, Xing H, Ye J. 2008. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57: 712717.
  • Yokoo T, Kitamuray M. 1996. Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 270: 123130.
  • Yoo HG, Shin BA, Park JS, Lee KH, Chay KO, Yang SY, Ahn BW, Jung YD. 2002. IL-1beta induces MMP-9 via reactive oxygen species and NF-kappaB in murine macrophage RAW 264.7 cells. Biochem Biophys Res Commun 298: 251256.
  • Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, Kim D, Kim HS, Cho SH, Song KS, Sangiorgi G. 2005. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 180: 3744.
  • Zhou J, Zhu P, Jiang JL, Zhang Q, Wu ZB, Yao XY, Tang H, Lu N, Yang Y, Chen ZN. 2005. Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. BMC Cell Biol 6: 25.